Introduction: inflammatory bowel diseases (IBD) - primarily Crohn’s disease (CD) and ulcerative colitis (UC) - are chronic disorders of the gastrointestinal tract characterized by persistent inflammation and immune dysregulation, involving genetic, epigenetic, microbiota-related, and environmental factors. Their diagnosis still relies on invasive methods such as colonoscopy, histology, and serum or fecal biomarkers, which show limitations in specificity and discriminative capacity. This scenario has driven the search for non-invasive tools such as microRNAs, small regulatory RNA fragments with high stability that could accurately differentiate between UC and CD. Objective: to evaluate recent evidence on the differential expression of various microRNAs in IBD and their utility as non-invasive diagnostic biomarkers, comparing them with conventional markers such as fecal calprotectin. Methodology: a narrative review was conducted based on a structured search in BVS, PubMed, Web of Science, and Scopus, using DeCS/MeSH terms related to “MicroRNAs,” “Inflammatory bowel disease,” “Crohn disease,” and “Ulcerative colitis.” Articles published in the last five years, in English or Spanish, evaluating the differential expression of microRNAs in IBD were included. Development: several microRNAs show characteristic expression patterns depending on the pathology. In UC, overexpression of miR-16-5p, miR-21-5p, miR-23a-5p, miR-24-3p, miR-29a-3p, miR-126-3p, miR-195-5p, and let-7f-5p has been reported, whereas miR-192-5p, miR-375-3p, and miR-422b-5p are downregulated (9,10,20). In CD, miR-21-5p, miR-16-5p, miR-155-5p, and miR-223-3p are overexpressed, with reduced levels of miR-192-5p and miR-375-3p. These microRNAs participate in key processes such as inflammation, apoptosis, autophagy, and epithelial barrier regulation, supporting their clinical potential. Moreover, some—such as miR-223 and miR-146b-5p—may surpass traditional biomarkers like fecal calprotectin in sensitivity and specificity. Conclusion: microRNAs represent strong candidates as non-invasive diagnostic biomarkers in IBD due to their biological stability, differential expression between UC and CD, and direct relationship with pathophysiological mechanisms. Although the evidence is promising, standardized clinical studies are still needed to validate their routine use in medical practice. General Area of Study: Clinical laboratory. Specific area of study: Molecular biology. Type of study: Narrative review.